Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist, and Executive Director of Employer Services at the City of Hope Comprehensive Cancer Center in Duarte, CA.

Concept of Anti-Estrogen Therapy for Lung Cancer Makes International News
Wed, 01/26/2011 - 18:41
Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

This week, Drs. Bouchardy and colleagues in Geneva published their report of lower rates of lung cancer death in women with breast cancer who received the anti-estrogen therapy tamoxifen compared with women with breast cancer who didn't receive tamoxifen, leading to some debate about whether the commercially available agent tamoxifen should be recommended as a treatment for lung cancer.

This particular study (in it's pre-publication form) was actually discussed by GRACE faculty member Mary Pinder from Moffitt Cancer Center in Tampa just over a year ago. The main concept is that the study reviewed a very large cohort of women in Geneva with breast cancer and compared outcomes in terms of lung cancer development and rates of death from lung cancer as noted in their registry for the group of women who received tamoxifen vs. those who did not. They didn't see a significant reduction in the rate of lung cancers developing, but they did see a much lower rate of lung cancer deaths compared with their calculated expectations in a model in the patients who received tamoxifen (13% of the expected number), compared with 76% of the expected calculation for those women with breast cancer who didn't receive tamoxifen.

As Dr. Pinder appropriately pointed out in her post from a year ago, we need to recognize that this is a retrospective analysis, and I think it's also important to highlight that the numbers of women with lung cancer ended up as pretty small, so it's hard to make too much out of results that would have different conclusion if just 1-2 more patients had a different outcome. Importantly as well, the comparison is to a calculation of expected results that are based on assumptions. Finally, as Dr. Pinder noted as well, there could be some related confounding factor, such as a medication for hot flashes induced by tamoxifen, or something about breast cancer itself that has a protective effect (after all, there was a non-significantly lower than expected rate of lung cancer deaths in the women with breast cancer who didn't receive tamoxifen, and that 24% would be trumpeted if it happened to achieve statistical significance).

On the other hand, these admittedly limited results are consistent with a finding from the Women's Health Initiative that showed a lower lung cancer survival for women who took hormone replacement therapy (HRT) (summarized here by Dr. Heather Wakelee from Stanford), just showing a result in the opposite direction with an anti-estrogen therapy.

So should we be recommending tamoxifen as a treatment for women with lung cancer? I agree with Dr. Pinder's assessment that these results are very intriguing and should lead us to increase our commitment to prospective trials that evaluate agents like tamoxifen or other hormone therapies such as aromatase inhibitors that are routinely used in breast cancer, as they may truly be effective interventions for lung cancer. However, they have their own side effects and costs, and in the absence of a higher level of evidence, I personally feel that the evidence we have now falls well short of what we would need to prescribe one of these agents as a lung cancer treatment. Because these are daily oral therapies, they would have the potential to be used on a longitudinal basis, such as after surgery for early stage disease or after chemo/radiation for locally advanced lung cancer, as well as in the advanced lung cancer setting. I would be very interested in participating in, or at least learning the results of, trials of these hormonal therapies in any of these settings.

The threshold for discussing and perhaps recommending discontinuation of HRT for women with lung cancer who are on it is different from the level of evidence I think you would need to recommend an anti-estrogen therapy. Here, I think the converging evidence, all pretty consistent, would lead me to want to discuss this with women on HRT, or considering HRT; I would say that the level of evidence warrants the potentially detrimental effect on lung cancer survival merits being factored into the equation of pros and cons of this complex question. In fact, I had a conversation with one such patient earlier today.

For now, this remains a murky question, but it's great to see momentum building for research in this field that could lead to better recommendations for our current patients and perhaps a new treatment approach for the future. Of course, what this means in terms of optimizint treatment for he men with lung cancer is still completely unknown. But we're adding pieces to the puzzle.

Next Previous link

Previous PostNext Post

Related Content

Mandarin LCVL
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit:…;  
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Blood Cancer OncTalk
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29